0+$+1&2+3'4*.+5...
TRANSCRIPT
!"#$%$#&'($)*#+,-*.'/0+$"+1&"2+3'"4*.+5
6-*.*+'.*+7*+$"+89::;
<$=.2$=+>?+@4'2($=AA$
B"$%*.C$A0+=D+,=.$"=
E*/'.AF*"A+=D+3($"$4'(+G+H$=(=2$4'(+@4$*"4*C
2$=.2$=?C4'2($=AA$I&"$A=?$A
J=A'K(*+L#%'"4*C+$"+3'"4*.+M*C*'.4-
$"+A-*+('CA+8+0*'.C
N'..*(+L?+J'A?+O*#?+89::P+:Q58R8S8RT
U.=2.*CC+$"+A-*+A.*'AF*"A+=D
F*A'CA'A$4+(&"2+4'"4*.
!"#$%&$'($")&$!"#$%&'($%)"*+',%*+,+-$,+-./+
,7*"A0S,7=+V*'.C+=D+U-'C*+!!!+,.$'(C
D=.+U'A$*"AC+6$A-+L#%'"4*#+J@313
3="4(&C$="$0$12")3454$#6$7"4($(85")4$52$9#8(:$1;'85<"$4:#=4$(:"($(:'$78#)#2>"(5#2$52$;'?5"2$4@8A5A")
B'(=''2$(=#$"8;4$#6$"$8"2?#;5C'?$4(@?3$="4$8"8')3$52$'D<'44$#6$*$;#2(:4&$,*4-"$W&*C+D=.+$F/.=%*#+&C*
=D+/'A$*"A+.*C=&.4*C+'"#+'//.=/.$'A*+A.$'(+#*C$2"+D=.+/-'C*+!!!+.'"#=F$)*#+A-*.'/*&A$4+A.$'(C+7$A-
/'A$*"AC+7$A-+'#%'"4*#+J@313+"**#+A=+K*+#*%*(=/*#?
EE$7:"4'$FFF$(85")4$='8'$525(5"('?$B'(=''2$,G.E$"2?$,GGH&$N$%*+A.$'(C+X:YZ[+C-=7*#+'+CA'A$CA$4'((0+C$2"$D$4'"A
#$DD*.*"4*+$"+C&.%$%'(\+7$A-+'+F*#$'"+/.=(="2'A$="+=D+A-*+C&.%$%'(+=D+8+F="A-C?
I8'"(:2"<:$JK$'($")$%-$%)./*$%0*+1.$%*++,-$,G0$,.EH
U.=2.*CC+$"+A-*+A.*'AF*"A+=D
F*A'CA'A$4+(&"2+4'"4*.
!"#$%&$'($")&$!"#$%&'($%)"*+',%*+,+-$,+-./+
]DD$4'40+K0+^$CA=(=20+$"+U*F*A.*_*#+@A&#$*C
NSCLC
Histologic
Group
Second-line
Pem vs. Docetaxel
First-line
Pem/Cis
vs. Gem/Cis
Maintenance
Pem vs. Placebo
Pem Doc Cis/Pem Cis/Gem Pem Placebo
Non-squamous n=205 n=194 n=618 n=634 n=325 n=156
Median OS, months 9.3 8.0 11.0 10.1 15.5 10.3
Adjusted HR (95% CI)
P value
0.78 (0.61–1.00)
0.048
0.84 (0.74–0.96)
0.011
0.70 (0.56–0.88)
0.002
Squamous n=78 n=94 n=244 n=229 n=116 n=66
Median OS, months 6.2 7.4 9.4 10.8 9.9 10.8
Adjusted HR (95% CI)
P value
1.56 (1.08–2.26)
0.018
1.23 (1.00–1.51)
0.050
1.07 (0.77–1.50)
0.678
Non-squamous = adenocarcinoma, large cell carcinoma, and other/indeterminate NSCLC histology
K<">)5#((5$LM$'($")&$0*+1.12/3#%%*++G
3'"4*.+M*C*'.4-+'A+A-*+.=&"#'K=&A
,& N"2<'8$54$"$>'2'(5<$4#;"(5<$?54'"4'$$OPQ$52:'85('?R
*& OM'83$)5S')3R$#85>52"('4$68#;$4(';$<'))4
E& F($54$<"@4'?$B3$>'2'(5<$")('8"(5#24$#6$"$:"2?6@)$#6$>'2'4
O0*+12'*'3$#8$T4,/(',$2'*'35R
H& F($54$#6('2$7#445B)'$(#$5?'2(563$(:'4'$>'2'(5<$)'45#24
B3$;#)'<@)"8$?5">2#454
P& TU"8>'('?V$U:'8"73$54$#2)3$'66'<(5A'$=:'2$"5;'?$"($(:'
")('8"(5#2$#6$(:'$?85A'8$>'2'O4R0$T0*+12'*/+%677/+#/1*5
M'"#=F$)*#+,.$'(C+7$A-+3,`aS+,'.2*A*#+,-*.'/$*C$"+,.*'AF*"AS"'$%*+J@313
,M!L1 ,LM<], 3, <MbBU 3bOO]J,
!J,L3,S: ]<NM <3 LCA.'c*"*4' 3(=C*#\+"=+K*"*D$A
!J,L3,S8 ]<NM U3 LCA.'c*"*4' 3(=C*#\+"=+K*"*D$A
,M!HB,] ]<NM U3 <*"*"A*4-ab@! 3(=C*#\+"=+K*"*D$A
,L1]J, ]<NM <3 <*"*"A*4-ab@! 3(=C*#\+"=+K*"*D$A
LHd]<NM ]<NM U3 LF2*" 3(=C*#\+"=+K*"*D$A
L<eeT9 OOU U3 L2=&.=" 3(=C*#\+"=+K*"*D$A
L<eeT9 OOU <3 L2=&.=" 3(=C*#\+"=+K*"*D$A
HO@8QY8f: OOU U3 HO@b 3(=C*#\+"=+K*"*D$A
1="'D'."$K N,+X.'C[ U3 @4-*.$"2 3(=C*#\+"=+K*"*D$A
!@!@+eY8: Ug3! U3 !@!@ 3(=C*#\+"=+K*"*D$A
,'.2.*A$" MdM U3 1$2'"# 3(=C*#\+"=+K*"*D$A
@=.'D*"$K .'DSh$"'C*\>]<NM8 U3 H'0*. 3(=C*#\+"=+K*"*D$A
N$2$A&F&F'K !<NMS: U3 UD$)*. 3(=C*#\+"=+K*"*D$A
Lc8:Q: >]<NM U3 LCA.'+c*"*4' 3(=C*#\+"=+K*"*D$A
L@LST9T >EL U3 J=%'.A$C 3(=C*#\+"=+K*"*D$A
!8#>8'44$52$(:'$(8'"(;'2($#6
;'("4("(5<$)@2>$<"2<'8
!"#$%&$'($")&$!"#$%&'($%)"*+',%*+,+-$,+-./+
]<NM+=.+gS!"#+O&A'A$="C+L44=.#$"2+A=
]A-"$4$A0+'"#+@F=h$"2+@A'A&C
@&#'+g?+*A+'(?+$%&'()*+(,%-,%-.-*!(/0*89:9P+8f5Tf
]<NMS,g!C+'"#+]<NM+O&A'A$="+SE$.*4A*#
N.="A+S+1$"*+@A&#$*C
@A� ]"A.0+3.$A*.$' ^M+D=.+UN@
X]<NM+F&A+`[
^M+D=.+b@
X]<NM+F&A+`[
!UL@@
O=h
J]iO+899f
LC$'A$4\+"*%*.S+G+($2-A
jCF=h*.C\
'#*"=4'.4$"=F'
X]<NM+F&A+`++Yf?QZ[
9?Tk
X9?eRS9?RR[
9?f:+l
X9?QRS:?:9[
l=%*.'((+/=/&('A$="
N$.CA+j+@!<JL1
U.=4?+!L@13
899f
L#*"=4'.4$"=F'\+J*%*.S
CF=h*.C
X]<NM+F&A+`+TTZ[
9?R:
X9?e9S:?88[
9?k8
X9?eYS:?f8[
]<NMS,g!C+'"#+]<NM+O&A'A$="+SE$.*4A*#
N.="A+S+1$"*+@A&#$*C
@A� ]"A.0+3.$A*.$' ^M+D=.+UN@
X]<NM+F&A+`[
^M+D=.+b@
X]<NM+F&A+`[
!UL@@
O=h
J]iO+899f
LC$'A$4\+"*%*.S+G+($2-A
jCF=h*.C\
'#*"=4'.4$"=F'
X]<NM+F&A+`++Yf?QZ[
9?Tk
X9?eRS9?RR[
9?f:+l
X9?QRS:?:9[
l=%*.'((+/=/&('A$="
N$.CA+j+@!<JL1
U.=4?+!L@13
899f
L#*"=4'.4$"=F'\+J*%*.S
CF=h*.C
X]<NM+F&A+`+TTZ[
9?R:
X9?e9S:?88[
9?k8
X9?eYS:?f8[
6]i<@<998
g=K'0'C-$
L@3b+899f
]<NM+O&A'A$="+`++X'(([ 9?eY
X9?8YS9?Y9[
JL
]BM,L3+X]B[ ]<NM+O&A'A$="+`+X'(([ 9?T8
X9?8QS9?RT[
;
bU,!OL1
X3-$"'[
]<NM+O&A'A$="+`+X'(([ 9?:R
X9?:9S9?8R[
;
U.=2.*CC+$"+A-*+A.*'AF*"A+=D
F*A'CA'A$4+(&"2+4'"4*.
!"#$%&$'($")&$!"#$%&'($%)"*+',%*+,+-$,+-./+
U.=2.*CC+$"+A-*+A.*'AF*"A+=D
F*A'CA'A$4+(&"2+4'"4*.
!"#$%&$'($")&$!"#$%&'($%)"*+',%*+,+-$,+-./+
3=F/'.$C="+=D+M*C/="C*C
123!+F&A'A$="C+7$A-+*.(=A$"$K+%C+1+456"47
A.'"C(=4'A$="C+7$A-+4.$)=A$"$K
W"<S;"2$NNX$*++GY$I"2>$1KNJ$*+,+
.+Q$7"8(5")$8'47#24'$8"('
89:&$;@("2( 8;<=>6<?$(8"24)#<"('?
.+Q$7"8(5")$8'47#24'$8"('
@A'A&C+=D+L4A$="'K(*+E.$%*.+O&A'A$="C+$"
1&"2+L#*"=4'.4$"=F'+,&F=.+@/*4$F*"C
• Z@2>$N"2<'8$[@("(5#2$N#24#8(5@;
OZN[NR$;@("(5#2$('4(52>
– !'86#8;'?$52$NZF1\<'8(565'?
)"B#8"(#85'4$"($ZN[N$45('4
• !:345<5"24$@4'?$?"("$52$8'")\(5;'$(#
>@5?'$(:'8"7'@(5<$?'<545#24$6#8
7"(5'2(4
– F6%89:&$;@("(5#20$>5A'$'8)#(525B
– F6$#(:'8$;@("(5#20$$8'<#;;'2?$(85")$#6
">'2($47'<565<$6#8$(:"($("8>'(
• PHQ$52<5?'2<'$#6$452>)'$?85A'8
;@("(5#24$";#2>$4";7)'4
– ?&6@A%89:&A%"2?$8;<=>6<?%;#4(
<#;;#2
]854$[LY$'($")&$1KNJ$*+,,&$1B4(8"<($NX1.P+/&
9#$;@("(5#2$?'('<('?
]X1K$O**QR
^L_X$O,.QR
^[ZH\1Z]$O.QR
`#@B)'$;@("2(4$OEQR
IX1_$O*QR
1]U,
9X1K
[^],
[^U$1[!
a^X*
!F]EN1
N.*W&*"4$*C+=D+!"A.$"C$4+M*C$CA'"4*+A=+]<NMS,g!C
.*('A$%*+A=+C*"C$A$%$A0a.*C$CA'"4*+$"+J@313
3-*F=S"'m%*
'#%'"4*#
J@313]<NM+F&A'"A
]<NM+,g!+`+^E+8"#S2*"+]<NM+,g!
]<NM+,g!+`+H31S8$
]<NM+,g!+`+!<NS:M$
]<NM+,g!+`+O],$
]<NM+,g!+`+^3n
]<NM+,g!+X#$DD+#=C$"2+C4-*#&(*C[
]<NM+F&A'"A+J@313
7$A-+'4W&$.*#+.*C$CA'"4*l
]<NM+,g!+`+4-*F=
U=A*"A+8"#S2*"+]<NM+,g!
3-*F=+!+]<NM+,g!
8"#S2*"+]<NM+,g!+`+4*A&_$F'K
8"#S2*"+]<NM+,g!+`+O],$
LK=&A+A-*+O],+2*"*+'"#+3'"4*.
• U:'$#2<#>'2'$'2<#?'4$"$(38#452'\S52"4'$8'<'7(#8$6#8
aL_$Ob@+"##',%B"+#1,cR
• F($54%#A'8\'D78'44'?$52$8'47#24'$(#$@26"A#@8"B)'$;5<8#\
'2A58#2;'2(")$<#2?5(5#24Y$4@<:$"4$$:37#D5"$#8$5#25C52>
8"?5"(5#240$b0*+12'*'%8CD'7/'*+'c&
• F($54$$<#24(5(@(5A')3$"<(5A"('?$52$4#;'$<"2<'84Y$B3
";7)565<"(5#2Y$$;@("(5#24$#8$$"@(#<852'$)##740
b0*+12'*'%677/+#/1*c&
• F($54$>##?$<"2?5?"('$6#8$("8>'('?$(:'8"75'4
MET response correlates with gene amplification
PHA-665752
PHA-665752
97 %
EXPEDIENCE
5.2NCI-
H1993
5.6SNU5
6.3HS746T
6.1GTL-16
6MKN-45
5.8EBC-1
MET
copy N°Cell Line
Hypoxia
(or HGF)
< 3 %
ADDICTION
200 cancer l. tested
O],+G+1&"2+3'"4*.
• 1;7)565<"(5#2$#6$[^U$#<<@84$52$,\.Q$#6$2#2\4;"))$<'))
)@2>$<"2<'8$O9KNZNRY$"44#<5"('?$=5(:$7##8$78#>2#454
• [^U$";7)565<"(5#2$52<8'"4'4$@7$(#$*+Q$52$(@;#84
:"8B#@852>$4#;"(5<$^L_X$;@("(5#24Y$=5(:$"<d@58'?
8'454("2<'$(#$^L_X$52:5B5(#84$O>'65(525B$"2?$'8)#(525BR
• !8'<)525<")$4(@?5'4$4@>>'4($(:'$78''D54('2<'$"2?$<)#2")
4')'<(5#2$#6$[^U$";7)565<"(5#2$52$^L_X$;@("2($9KNZN
• U:'$<#;B52"(5#2$#6$'8)#(525B$"2?$"$['($;1B$5;78#A'4
78#>8'445#2\68''$4@8A5A")$"2?$#A'8"))$4@8A5A")$52$9KNZN
7"(5'2(4$4(8"(565'?$6#8$:5>:$['($'D78'445#2
O*AOLK+`+].(=A$"$K+%C+].(=A$"$K+L(="*+$"
U.*%$=&C(0+,.*'A*#+L#%'"4*#+J3@13
• ['([1B0$;#2#A")'2($"2(5B#?3$(#
['(
– !8'A'2(4$['($"<(5A"(5#2$B3
:'7"(#<3('$>8#=(:$6"<(#8
• ^L_X$;@("(5#24$52$4(@?3$7#7@)"(5#2
– ['($?5">2#4(5<\7#45(5A'$7#7@)"(5#20
5;B")"2<'?$#2$['([1B$"8;
– ['($?5">2#4(5<\2'>"(5A'$7#7@)"(5#20
5;B")"2<'?$#2$7)"<'B#$"8;
• !8'?'652'?$['($?5">2#4(5<\7#45(5A'
7#7@)"(5#2
– U@;#8$4";7)'4$=5(:$e$P+Q$(@;#8
<'))4$?547)"352>$;#?'8"('$#8$4(8#2>
['($4("5252>$B3$FaN
K75>')$`XY$'($")&$1KNJ$*+,,&$1B4(8"<($.P+P
Growth
Migration
Survival
No
activity
['( ['(
aL_ aL_
['([1B
O*AOLK+`+].(=A$"$K+%C+].(=A$"$K+$"
L#%'"4*#+J3@135+UN@+'"#+b@
• 9#$!_K$#8$JK$B'2'65($(#$"??52>$['([1B$(#$'8)#(525B$52$FUU$7#7@)"(5#2
• ['([1B$f$'8)#(525B$"44#<5"('?$=5(:$4@8A5A")$B'2'65(4$52$['(\7#45(5A'
7#7@)"(5#2
b&A4=F* !,,
U=/&('A$="
X"+o+:eQ[
O*A+E$'2"=CA$4SU=C$A$%*
U=/&('A$="
X"+o+RR[
O*A+E$'2"=CA$4SJ*2'A$%*
U=/&('A$="
X"+o+R8[
O*AOLK
`+].(=A$"$K
X"+o+Rf[
U('4*K=
`+].(=A$"$K
X"+o+Rk[
O*AOLK
`+].(=A$"$K
X"+o+eY[
U('4*K=
`+].(=A$"$K
X"+o+e:[
O*AOLK
`+].(=A$"$K
X"+o+e:[
U('4*K=
`+].(=A$"$K
X"+o+e:[
['?5"2$!_KY$;#4 *&* *&/ *&G ,&P ,&H *&.
" aX$OGPQ$NFR ,&+G$O+&.E\,&/*R +&PE$O+&*g\+&GGR ,&g*$O+&GG\E&E*R
" E$A")@' &/G &+H &+P
['?5"2$JKY$;#4 g&G .&H ,*&/ E&g g&, ,P&E
" aX$OGPQ$NFR +&g+$O+&P+\,&*gR +&E.$O+&,G\+&.*R ,&.g$O+&.G\E&GGR
" E$A")@' &EH &++* &,/
K75>')$`XY$'($")&$1KNJ$*+,,&$1B4(8"<($.P+P&
O*AOLK5+@'D*A0+'"#+O*A+]_/.*CC$="+'C+'
U.=2"=CA$4+N'4A=.
• 1^$78#65)'$52$['([1B$f$'8)#(525B$"8;$45;5)"8$(#$7)"<'B#$f$'8)#(525B
– a5>:'8$68'd@'2<3$#6$7'857:'8")$'?';"$52$['([1B$"8;
• ['($'D78'445#2$"44#<5"('?$=5(:$=#84'$#@(<#;'$52$7)"<'B#$f$'8)#(525B$"8;
– P*Q$#6$(544@'$4";7)'4$6#@2?$(#$B'$['($?5">2#4(5<$7#45(5A'
b&A4=F* U('4*K=+`+].(=A$"$K
O*A+E$'2"=CA$4+U=C$A$%*
X"+o+RR[
O*A+E$'2"=CA$4+J*2'A$%*
X"+o+R8[
['?5"2$!_KY$;#4 ,&P *&.
" aX$OGPQ$NFR ,&.,$O+&G/\E&+*R
" E$A")@' &+/
['?5"2$JKY$;#4 E&g ,P&E
" aX$OGPQ$NFR *&/,$O,&EH\P&+GR
" E$A")@' &++H
K75>')$`XY$'($")&$1KNJ$*+,,&$1B4(8"<($.P+P&
@W&'F=&C+3*((+3'.4$"=F'+=D+A-*+1&"2• `'("5)'?$>'2#;5<$"2")3454$#6$4d@";#@4$<'))$)@2>$<"2<'84$:"4
5?'2(565'?$4'A'8")$2'=$7#('2(5")$(:'8"7'@(5<$("8>'(4
<*"* ]%*"A+,0/* N.*W&*"40
_L_X, 1;7)565<"(5#2 *+\*PQ
_L_X* [@("(5#2 PQ
!F]EN1 [@("(5#2 GQ
!U^9 [@("(5#2h`')'(5#2 ,gQ
NN9`, 1;7)565<"(5#2 gQ
N`]9*1 `')'(5#2h[@("(5#2 HPQ
!`L_X1 1;7)565<"(5#2h[@("(5#
2
GQ
^L_X 1;7)565<"(5#2 ,+Q
[NZ, 1;7)565<"(5#2 ,+Q
IX1_ [@("(5#2 EQ
``X* [@("(5#2 HQ
^XII* 1;7)565<"(5#2 *Q
F2$/EQ$#6$)@2>$KNN4$='$<"2
2#=$5?'2(563$"$7#445B)'
(:'8"7'@(5<$("8>'(
U"8>'(4$=5))$2''?$(#$B'
A")5?"('?
52$78'\<)525<")$;#?')4
_L_X,h*Y$!F]EN1$"2?$``X*
52:5B5(#8$(85")4$"8'$7)"22'?$#8
#2>#52>
a";;'8;"2$!&$'($")&$!8#<&$F1KZN$*+,,
,'.2*A$"2+CA*F+4*((+C*(DS.*"*7'(+/'A-7'0C
L($C="+OM+*A+'(?+i?+U'A-=(?+89::P+88e5:TQ
3&..*"A+3="4*/A+=D+U-'.F'4=2*"=F$4C
!89(&*:+*(,*%;0**"&&*<&,()&*+(9*=>>?@*A5BCD5E6BD
U.*#$4A$%*+O=(*4&('.+O'.h*.C+D=.+M*C/="C*+A=
3-*F=A-*.'/0+$"+J@313
Gene Abnormality Drug Response
p53 Mutation Multiple
KRAS Mutation Platinum
!-tubulin Increased isotype 3 Taxanes
RRM1 Increased expression Gemcitabine
ERCC1 Increased expression Platinum
BRCA1 Increased expression Platinum
Thymidylate synthase Increased expression Antifolates
EGFR mutation Present Platinum
!,L3L+L#p&%'"A+,.$'(
U-'.F'4=2*"=F$4C5+V*C+=.+J=;
]M33:
^$2-
1=7
,@
,@
1=7
1=7
^$2-
^$2-
Profile 4
Profile 3
Profile 2
Profile 1
U"D"2'4
+U*F++++
3$Ca<*F
3$CaU*F
3="A.=(
3="A.=(
3="A.=(
3="A.=(
N#2(8#)$i$52A'4(5>"(#84V$<:#5<'$#6$<547)"(52\B"4'?$?#@B)'(
!85;"83$'2?7#52($i$$E+Q$52<8'"4'$52$JK-$U85")$K("(@4$"4$W@)3$*+,,i$*/Ph.++$7"(5'2(4
U-'C*+!!+@A�+=D+U.*=/*.'A$%*+3$CaU*F+$"
@A'2*+!!!'+J8+"="SCW&'F=&C+J@313
@A'2*+!!!'+J8
K0+O*#+X`3,
@4'"+`+U],[
Joee
3$C+QY+F2a+F8+G
U*F+Y99+F2aF8
_+e+We7hC
M*CA'2$"2+K0
3,+C4'"+'"#
U],@&.2*.0
H$=F'.h*.+LCC*CCF*"A
,@\+,,NS:\+]8N:\+]M33:\+HM3L:
XN&"4A$="'(+!F'2$"2+3-'"2*C[
U.$F'.0+*"#+/=$"A+5+bMM
@*4="#'.0+*"#+/=$"AC+5/3M\UN@\b@\+A&F=.+#=7"CA'2$"2\+A=_$4$A0
]U!3+,.$'(])?'8)3$U"(5'2(4$!2?5A5?@")5C'?$3:';#(:'8"73$U85")
85:+M'"#=F$)'A$="
!"#$%$#&'($)*#+L.F 3="A.=(+L.F
@W&'F=&C+3*((+3'.4$"=F'
V*C J= ]<NM+O&A+` bDD+@A�
]M33:+(=7
MMO:+-$2-
]M33:+-$2-
MMO:+(=7
]M33:+(=7
MMO:+(=7
]M33:+-$2-
MMO:+-$2-
3'.K=/('A$" <*F4$A'K$"* 3'.K=a<*F ,'_'"*
]M33:+(=7
,@+-$2-
]M33:+-$2-
,@+(=7
]M33:+(=7
,@+(=7
]M33:+-$2-
,@+-$2-
3'.K=/('A$" U*F*A.*_*# 3'.K=aU*F
V*C
J=
MMO:+(=7 MMO:+-$2-
<*F4$A'K$"* ,'_'"*
,.*'AF*"A+K'C*#+="+!"%*CA$2'A=.Cq+U.*D*.*"4*
U!C+5+<?+@$F="+G+<?+@4'2($=AA$
B"$%*.C$A0+=D+@=&A-+3'.=($"'+X^=(($"2C+3'"4*.+3*"A*.[+G+B"$%*.C$A0+=D+,=.$"=
]<NM+O&A+`
V*C
@&FF'.0
• ]<NMS,g!C+C-=&(#+K*+A-*+/.*D*..*#+D$.CA+($"*+A.*'AF*"A+4-=$4*
D=.+/'A$*"AC+7$A-+A&F=&.C+-'.K=&.$"2+]<NM+C*"C$A$)$"2S
F&A'A$="C?+L1g+$"-$K$A=.C+&"#*.+$"%*CA$2'A$="C?
• !"+F=.*+A-'"+R9Z+=D+CW&'F=&C+4*((+4'.4$"=F'+=D+A-*+(&"2+'
/=A*"A$'(+A-*.'/*&A$4+A'.2*A+-'C+K**"+$#*"A$D$*#?+J**#+A=+K*
%*.$D$*#+$"+/.*4($"4'(+F=#*(C?
• ,-*.'/*&A$4+4-=$4*C+K'C*#+="+-$CA=(=20+'.*+A-*+4&..*"A
CA'"#'.#+=D+4'.*+D=.+A-*+F'p=.$A0+=D+=&.+/'A$*"AC
• ,-*+#*D$"$A$="+=D+-=F=2*"*=&C+2*"*A$4+C&K2.=&/C+=D+A&F=.C
'"#+A-*+C*'.4-+D=.+$"#$%$#&'($)*#+'//.='4-*C+$C+A-*+7'0+A=
C&KCA$'"A$'((0+$"4.*'C*+C&.%$%'(++*_/*4A'"40+$"+A-$C+#$C*'C*?
r!D+!+C'7+D&.A-*.+A-'"+=A-*.
F*"\+$A+7'C+K*4'&C*+!+CA==#
="+A-*+C-=&(#*.C+=D+2$'"ACs
r!D+!+-'%*+*%*.+F'#*+'"0+%'(&'K(*+#$C4=%*.$*C\
$A+-'C+K**"+#&*+F=.*+A=+/'A$*"A+'AA*"A$="\
A-'"+A=+'"0+=A-*.+A'(*"As